MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Thermo Fisher Scientific Inc

Închisă

SectorSănătate

489.21 1.42

Rezumat

Modificarea prețului

24h

Curent

Minim

480.45

Maxim

491.12

Indicatori cheie

By Trading Economics

Venit

194M

1.8B

Vânzări

795M

11B

P/E

Medie Sector

30.121

63.778

EPS

6.1

Randament dividend

0.35

Marjă de profit

16.007

Angajați

125,000

EBITDA

377M

3B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+38.06% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.35%

2.39%

Următoarele câștiguri

23 apr. 2025

Data viitoare de dividende

15 apr. 2025

Următoarea dată ex-dividende

13 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-40B

189B

Deschiderea anterioară

487.79

Închiderea anterioară

489.21

Sentimentul știrilor

By Acuity

33%

67%

106 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Thermo Fisher Scientific Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 feb. 2025, 14:05 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30 ian. 2025, 11:43 UTC

Câștiguri

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23 oct. 2024, 10:43 UTC

Câștiguri

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25 feb. 2025, 14:09 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25 feb. 2025, 13:41 UTC

Achiziții, Fuziuni, Preluări

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25 feb. 2025, 13:40 UTC

Achiziții, Fuziuni, Preluări

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25 feb. 2025, 13:40 UTC

Achiziții, Fuziuni, Preluări

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25 feb. 2025, 13:40 UTC

Achiziții, Fuziuni, Preluări

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25 feb. 2025, 13:40 UTC

Achiziții, Fuziuni, Preluări

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25 feb. 2025, 13:39 UTC

Achiziții, Fuziuni, Preluări

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25 feb. 2025, 13:33 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25 feb. 2025, 13:32 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25 feb. 2025, 13:32 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24 feb. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24 feb. 2025, 23:03 UTC

Top știri
Achiziții, Fuziuni, Preluări

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24 feb. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Deal Could be Announced This Week, Sources Say -- WSJ

24 feb. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30 ian. 2025, 11:06 UTC

Câștiguri

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30 ian. 2025, 11:05 UTC

Câștiguri

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30 ian. 2025, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Rev $11.4B >TMO

30 ian. 2025, 11:00 UTC

Câștiguri

Thermo Fisher 4Q EPS $4.78 >TMO

30 ian. 2025, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30 ian. 2025, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Net $1.83B >TMO

30 ian. 2025, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16 dec. 2024, 22:03 UTC

Top știri

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23 oct. 2024, 10:02 UTC

Câștiguri

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23 oct. 2024, 10:02 UTC

Câștiguri

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23 oct. 2024, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23 oct. 2024, 10:00 UTC

Câștiguri

Thermo Fisher 3Q EPS $4.25 >TMO

23 oct. 2024, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Comparație

Modificare preț

Thermo Fisher Scientific Inc Așteptări

Obiectiv de preț

By TipRanks

38.06% sus

Prognoză pe 12 luni

Medie 666.81 USD  38.06%

Maxim 715 USD

Minim 570 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruThermo Fisher Scientific Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

14

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 513.14Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

106 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar